Merck discontinues a crucial antibiotic despite superbug resistance concerns

Bulletin

STAT News reported on September 28 that Merck has discontinued Recarbrio in the United States, removing from the market an antibiotic regarded as an important tool against drug-resistant infections.

Recarbrio, a combination therapy, had been positioned as an option for treating certain difficult bacterial infections, including cases involving pathogens resistant to more common antibiotics. According to the report, the discontinuation comes despite ongoing concern within public health circles about rising antimicrobial resistance, often referred to as the superbug threat.

The report frames Merck’s decision as part of a broader, long-documented pattern in the pharmaceutical industry, in which antibiotics, particularly newer or narrowly used ones, often fail to generate the commercial returns that manufacturers require to justify continued production. Antibiotics differ from many other drug classes in that they are typically used for short courses and held in reserve for severe cases, which limits the sales volume that sustains their availability.

STAT News notes that the loss of a last-resort therapy such as Recarbrio reduces the tools available to clinicians treating patients with infections that no longer respond to standard treatments. The discontinuation adds to concerns among infectious disease specialists and public health officials about a shrinking pipeline and dwindling supply of antibiotics effective against resistant bacteria, even as resistant infections continue to be identified in hospitals and clinical settings.